TB-MR

Multidrug-resistant tuberculosis is formally defined as an active infection by Mycobacterium tuberculosis exhibiting confirmed resistance to the two most potent first-line anti-tuberculosis medications, isoniazid and rifampicin ^[1][2]. Resistance typically originates from specific chromosomal mutations, such as alterations in the rpoB and katG genes, which arise following inconsistent drug exposure or monotherapy ^[2]. When additional resistance extends to fluoroquinolones or other critical second-line agents, the infection may be classified under broader drug-resistant or extensively drug-resistant categories ^[3].

Active infection manifests as a systemic illness characterized by a protracted clinical course, accompanied by significantly higher morbidity and mortality rates than standard tuberculosis ^[4]. Patients frequently experience substantial pulmonary deterioration and long-term respiratory impairment following disease resolution ^[3]. The underlying pathophysiology involves persistent bacterial replication driven by genetic adaptations that neutralize conventional pharmacological interventions, though specific symptomatic presentations align with typical pulmonary tuberculosis pathology ^[1][2].

Multidrug-resistant tuberculosis cases have been documented across all surveyed countries, with concentrated burdens observed in Eastern Europe, Russia, Asia, and sub-Saharan Africa ^[1]. The infection serves as a predominant contributor to global infectious disease mortality, with delayed detection methods potentially exacerbating case incidence ^[2]. Regional variations are pronounced, as evidenced by resistance rates reaching nearly fifty percent among previously treated cohorts in specific humanitarian settings like Somalia ^[1]. Outbreaks tend to cluster within environments featuring compromised host immunity, particularly among populations living with HIV, where transmission dynamics can accelerate despite generally attenuated bacterial fitness ^[1].

Multidrug-resistant tuberculosis spreads primarily through airborne respiratory droplets expelled during coughing by individuals with active pulmonary disease ^[1]. The infectious potential of these resistant strains remains comparable to that of drug-susceptible variants, maintaining high transmissibility within exposed communities ^[3]. Secondary spread accelerates markedly in environments where immune defenses are impaired, facilitating rapid colonization among vulnerable contacts ^[1].

Public health strategies emphasize the strict adherence to standardized multi-drug therapeutic regimens to prevent the emergence of resistant bacterial strains ^[1]. International monitoring frameworks, such as those coordinated by regional disease prevention authorities, utilize targeted screening of high-risk migrant populations to assess transmission threats to local communities ^[1]. Comprehensive prevention protocols further require integrated management approaches that address pathogenesis, diagnostic accuracy, and therapeutic consistency to mitigate future resistance development ^[3].

1. 1 Wikipedia contributors. Multidrug-resistant tuberculosis - Wikipedia [Internet]. Wikipedia. cited 4 Sept 2026. Available from: https://en.wikipedia.org/wiki/Multidrug-resistant_tuberculosis
2. 2 Wulandari DA et al. Multidrug-resistant tuberculosis. Clin Chim Acta. 2024 Jun 1. PMID: 38697459. doi: 10.1016/j.cca.2024.119701. PubMed: https://pubmed.ncbi.nlm.nih.gov/38697459/
3. 3 Dheda K et al. Multidrug-resistant tuberculosis. Nat Rev Dis Primers. 2024 Mar 24. PMID: 38523140. doi: 10.1038/s41572-024-00504-2. PubMed: https://pubmed.ncbi.nlm.nih.gov/38523140/
4. 4 Lange C et al. Management of drug-resistant tuberculosis. Lancet. 2019 Sep 14. PMID: 31526739. doi: 10.1016/S0140-6736(19)31882-3. PubMed: https://pubmed.ncbi.nlm.nih.gov/31526739/